Q2 FY2026 EarningsQ2 FY26 results were mixed relative to consensus, with a top-line beat but a wider-than-expected loss. Revenue of $1.49M outperformed the $0.89M consensus (+67.4%), while GAAP EPS of -$0.07 missed the -$0.0533 mean estimate due to significant non-cash items and debt extinguishment costs. A successful $130M convertible note financing has extended the cash runway into 2028, and the OCU410 Phase 3 trial remains on track for initiation this quarter.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Ocugen(OCGN) the Revenue is 1.488 M (+8.38%), Beat estimate;the EBIT is -16.44 M (-19.2%), Beat estimate;the EPS is -0.07 (-40%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B8.38%
0.00B35.26%
+0.00B43.64%
EBITExceed expectations
-0.02B19.20%
-0.02B31.04%
+0.00B11.84%
EPSMiss expectations
-0.0740.00%
-0.05336.66%
-0.016733.34%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf